5. Conclusions
The UGT1A1*6 andUGT1A1*28 genetic polymorphisms especially when patients carried homozygous of these variants were significantly associated with irinotecan induced severe toxicities such as neutropenia and diarrhea in Asian cancer patients. The findings of this analysis suggest that both of the UGT1A1*6 and *28 genetic variants should screen in Asian cancer patients to reduce irinotecan toxicities substantially. Also, suggested to avoid high doses of irinotecan (>150mg/m2) to reduce toxicities significantly. It is high time to prepare national guidelines for adhering routine preemptive screening of UGT1A1*6 andUGT1A1*28 variants in cancer patients before prescribing irinotecan. This may facilitate rapid translation of UGT1A1*6 andUGT1A1*28 pharmacogenomics into the clinical practice in the form of precision irinotecan therapy.
Supplementary Materials: Supplementary Table 1: Quality assessment of the included studies by Newcastle Ottawa Scale (NOS).
Author Contributions:Conceptualization, CS, CA and MB; Data curation CA, NV, YH and NN; Formal analysis; MB, SS and NV; Methodology, CS, CA, NV and MB; Project administration, PJ and JR; Supervision, CS; Writing—original draft, CA, MB, NV and CS. The final manuscript was revised by all authors, and this version was approved to be published.
Funding: This study was supported by grants from the (1) Mahidol University International Postdoctoral Fellowship, Mahidol University (2) Faculty of Medicine, Ramathibodi Hospital, Mahidol University (3) the Health System Research Institute under Genomics Thailand Strategic Fund, (4) The International Research Network-The Thailand Research Fund (IRN60W003).
Institutional Review Board Statement: Not applicable since it was a meta-analysis.
Informed Consent Statement: Not applicable
Data Availability Statement:This manuscript does not contain any associated data. However, the raw data supporting the findings of this study is freely available upon reasonable request.
Acknowledgments: The authors thank the staffs of Pharmacogenomic and Personalized Medicine of Ramathibodi Hospital.
Conflicts of Interest: The authors declare that they have no conflicts of interest.